2023
Preliminary results of a phase II trial with sacituzumab govitecan-hziy in patients with recurrent endometrial carcinoma overexpressing Trop-2.
Santin A, McNamara B, Siegel E, Harold J, Mutlu L, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Dottino P, Schwartz P, Bellone S. Preliminary results of a phase II trial with sacituzumab govitecan-hziy in patients with recurrent endometrial carcinoma overexpressing Trop-2. Journal Of Clinical Oncology 2023, 41: 5599-5599. DOI: 10.1200/jco.2023.41.16_suppl.5599.Peer-Reviewed Original ResearchRecurrent endometrial carcinomaSacituzumab govitecan-hziyTrop-2 overexpressionPhase 2 trialEndometrial carcinomaUterine serous carcinomaTrop-2Endometrioid adenocarcinomaSerous carcinomaClinical activityMetastatic triple-negative breast cancerAnti-Trop-2 antibodyGrade 3 endometrioid adenocarcinomaTriple-negative breast cancerAdequate bone marrowUnexpected safety signalsMetastatic urothelial cancerClear cell histologyPhase II trialSystemic corticosteroid usePlatinum-based chemotherapyFavorable safety profileDurable disease controlRemarkable clinical activityStage 1
2022
Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer
Makker V, Colombo N, Herráez A, Santin A, Colomba E, Miller D, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim Y, Guerra E, Sanli U, McCormack M, Smith A, Keefe S, Bird S, Dutta L, Orlowski R, Lorusso D. Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer. Obstetrical & Gynecological Survey 2022, 77: 275-276. DOI: 10.1097/ogx.0000000000001032.Peer-Reviewed Original ResearchEndometrial cancerRecurrent endometrial cancerSecond-line treatmentAdvanced endometrial cancerPlatinum-based chemotherapyRecurrent endometrial carcinomaTyrosine kinase inhibitorsEndometrial carcinomaOptimal treatmentDisease progressionLimited efficacySingle agentKinase inhibitorsLenvatinibCancerTreatmentPembrolizumabLittle consensusChemotherapyCarcinomaProgression
2008
Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu
Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. International Journal Of Gynecology & Obstetrics 2008, 102: 128-131. PMID: 18555254, DOI: 10.1016/j.ijgo.2008.04.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCA-125 AntigenDisease ProgressionEndometrial NeoplasmsFemaleGene Expression Regulation, NeoplasticGenes, erbB-2HumansImmunohistochemistryIn Situ Hybridization, FluorescenceNeoplasm Recurrence, LocalReceptor, ErbB-2TrastuzumabConceptsMetastatic endometrial carcinomaHER2/neuEndometrial carcinomaSingle agentCA-125 evaluationHER2/neu receptorRecurrent metastatic diseaseRecurrent endometrial carcinomaEffect of trastuzumabSerial CT scansViable therapeutic optionC-erbB2 gene amplificationSalvage chemotherapyClinical responseMetastatic diseaseTrastuzumab treatmentTherapeutic optionsStudy criteriaDisease progressionCT scanPatientsTrastuzumabNeu receptorChemotherapyRadiation treatmentRecurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole
Bellone S, Shah HR, McKenney JK, Stone PJ, Santin AD. Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole. American Journal Of Obstetrics And Gynecology 2008, 199: e7-e10. PMID: 18550023, DOI: 10.1016/j.ajog.2008.04.012.Peer-Reviewed Original Research